Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Grows By 24.9%

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the target of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 73,700 shares, an increase of 24.9% from the May 15th total of 59,000 shares. Based on an average daily volume of 27,700 shares, the short-interest ratio is presently 2.7 days. Currently, 1.5% of the company’s shares are short sold.

Hedge Funds Weigh In On Aprea Therapeutics

Several institutional investors have recently made changes to their positions in the company. Stonepine Capital Management LLC increased its stake in shares of Aprea Therapeutics by 8.8% during the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after buying an additional 12,047 shares during the period. BNP Paribas Financial Markets purchased a new position in shares of Aprea Therapeutics during the fourth quarter valued at $43,000. LPL Financial LLC purchased a new position in shares of Aprea Therapeutics during the fourth quarter valued at $53,000. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Aprea Therapeutics during the fourth quarter valued at $116,000. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Trading Down 0.7%

Shares of Aprea Therapeutics stock opened at $1.77 on Friday. The firm has a market cap of $9.78 million, a P/E ratio of -0.75 and a beta of 1.22. Aprea Therapeutics has a 12 month low of $1.41 and a 12 month high of $5.01. The stock’s fifty day moving average price is $1.70 and its 200-day moving average price is $2.58.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.01). The firm had revenue of $0.16 million for the quarter. Aprea Therapeutics had a negative net margin of 1,095.02% and a negative return on equity of 68.39%. Analysts forecast that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Wedbush reiterated an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, March 25th.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.